Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes: targets pyroglutamated Aβ in plaques & halflife : ~12.1 days or ~5 h (caffeine)

Use the filters below to narrow your results.

generic:
None (1)
brand:
Kisunla (1)
classes: (Click arrow to add another value)
mechanism:
None (1)
uses:
Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1)
starting dose:
700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1)
preparations:
350 mg/20 mL vial for IV infusion (1)
fda max:
1400 mg q4w (1)
routes:
IV infusion every 4 weeks (1)
onset:
Amyloid PET clearance within months; cognitive benefit over 18 months (1)
duration:
Treatment can be discontinued upon achieving amyloid clearance (1)
halflife: (Click arrow to add another value)
bioavailability:
100% (IV) (1)
pregnancy:
Limited data (1)
legal:
Rx; ARIA monitoring required (1)

Showing below up to 1 result in range #1 to #1.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"